Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Matias says his time at NVIDIA gave him an insider view of AI progress—more compute, better data, better models—converging with neurobiology. That visibility helped convince him a venture fund focused on brain and mental health could work. He calls it one of the lucky breaks behind SciMed's launch.

Related Insights

Given the strong parallels in how AI models and brains represent information, studying AI provides a powerful, accessible, and faster proxy for neuroscience research. As Max Hodak's friends at top AI labs joke, it is simply "way easier to do neuroscience on the models."

Matias says precision neuroscience is limited by messy, non-normalized data and by a missing business model. Wearables and other data exist, but few multidisciplinary teams turn them into a source of truth or deploy them with aligned incentives. He lists these practical gaps alongside the brain's underlying complexity.

Matias says old medical devices were single-indication assets, but brain-computer interfaces are becoming horizontal platforms. Miniaturization plus better algorithms enable closed-loop read-and-stimulate systems, and neurotech's circuit-level interface makes many psychiatric applications plausible. That shift is why he is excited about devices despite their historical reputation.

Despite high scientific risk, generalist investors are entering neuroscience because it's a massive, underserved market. The potential for significant returns from even incremental improvements, combined with the huge societal and economic impact, creates a strong financial thesis for this 'white space'.

For a decade, AI failed to produce developable therapeutics. In the last two years, however, new models have matured, making AI-driven drug design and discovery an explosive and attractive investment area for the first time.

Treating the brain as a computational device allows for an engineering-driven approach to solving neurological issues. This yields more predictable results and faster progress compared to the "random walk" of small molecule drug discovery, which often ends in failure after years of research.

While new technology is a factor, renewed investment in neuroscience is heavily driven by its "greenfield" status. Unlike crowded markets like oncology, many neurological disorders lack effective treatments, offering significant, untapped commercial potential for large pharmaceutical companies seeking new growth areas.

Matias says many hot biotech companies use AI without being AI-first; the harder problem is delivery. For RNA and oligo therapies, he highlights crossing the blood-brain barrier with brain shuttles and getting compounds inside the right cell. Those enabling technologies are where SciMed is seeing interesting companies.

The recent increase in neurology-focused investment and M&A isn't just a cyclical market trend. It's driven by fundamental scientific progress, including validated biological targets and improved biomarker strategies. These advances are de-risking a historically challenging field, making investors more confident in long-term commitments beyond typical market cycles.

A neuroscientist-led startup is growing live neurons on electrodes not just for compute efficiency, but as a platform to discover novel algorithms. By studying how biological networks process information, they identify neuroscience principles that can be used as software plugins to improve current AI models and find successors to the transformer architecture.